FINNENCE ▪ THE WIRE FILE
THE WIRE · № 72942
SEC Filing■ Unclear/unknown
MU filed 10-K on 2026-10-09
KINDSEC Filing
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN2026-10-09 00:00 UTC
LAST UPDATE2026-10-09 00:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A routine annual 10-K provides audited detail on Micron's revenue mix, margins, and risk factors, which can reset analyst estimates.
Annual filing refreshes Micron fundamentals baseline
CATALYST TO WATCH
Guidance or risk-factor changes in the filing
MAIN RISK
Weak disclosures could pressure the stock
FULL DISPATCH
MU (CIK 0000723125) filed a 10-K on 2026-10-09.
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTMicron · MU
AFFECTEDSemiconductors
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer — Shanghai Henlius Biotech2026-10-08 12:00 UTC
New Phase 3 trial: A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer — Shanghai Henlius Biotech2026-10-08 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Phase 3 Study of Povorcitinib Phosphate in Chinese Adults With Nonsegmental Vitiligo — Dermavon Holdings Limited2026-10-08 12:00 UTC
New Phase 3 trial: A Phase 3 Study of Povorcitinib Phosphate in Chinese Adults With Nonsegmental Vitiligo — Dermavon Holdings Limited2026-10-08 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes — Amgen2026-10-08 12:00 UTC
New Phase 3 trial: Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes — Amgen2026-10-08 12:00 UTC
→INFERENCEfilings generate company commentary
Phase 3 results posted: Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD) — PTC Therapeutics2026-10-08 12:00 UTC
Phase 3 results posted: Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD) — PTC Therapeutics2026-10-08 12:00 UTC
→INFERENCEfilings generate company commentary
Phase 3 results posted: A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems — Bayer2026-10-08 12:00 UTC
Phase 3 results posted: A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems — Bayer2026-10-08 12:00 UTC
→INFERENCEfilings generate company commentary
Phase 3 results posted: Safety Study of Viaskin Peanut to Treat Peanut Allergy — DBV Technologies2026-10-08 12:00 UTC
Phase 3 results posted: Safety Study of Viaskin Peanut to Treat Peanut Allergy — DBV Technologies2026-10-08 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.